Healthy
Conditions
Keywords
Factor D Inhibitor, Complement, Danicopan, Pharmacokinetics, Food-effect, Age-effect
Brief summary
This will be an open-label, 2-part study. Part 1 will be a randomized, 2-sequence, 2-period crossover, food-effect study in healthy young adult participants. Part 2 will be a 1-period age-effect study in healthy elderly male participants.
Detailed description
This will be an open-label, 2-part study. Part 1 will be a randomized, 2-sequence, 2-period crossover, food-effect study in healthy young adult participants. Part 2 will be a 1-period age-effect study in healthy elderly male participants.
Interventions
DRUGDanicopan
A single dose of danicopan (200 milligrams) will be administered orally.
Sponsors
Alexion Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
This will be 2-part study. Part 1 will be a randomized, 2-sequence, 2-period crossover study, and Part 2 will be a 1-period study.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Young adult males or females, between 18 and 55 years of age (Part 1 only). 2. Elderly male participants aged ≥ 65 years of age at screening (Part 2 only). 3. Body mass index in the range of 18.0 to 32.0 kilograms (kg)/meter squared, inclusive, with a minimum body weight of 50.0 kg at screening. 4. No clinically significant history or presence of electrocardiogram findings at screening. 5. Non-sterile male participants must agree to abstinence or use a highly effective method of contraception. 6. Female participants of childbearing potential must either agree to abstinence or to use, with their male partner, a highly effective method of contraception (Part 1 only).
Exclusion criteria
1. Clinically significant laboratory abnormalities. 2. Pregnant or lactating (Part 1 only). 3. History of any medical or psychiatric condition or disease that might limit the participant's ability to complete or participate in this clinical study, confound the results of the study, or pose an additional risk to the participant by their participation in the study. 4. History or presence of drug or alcohol abuse within previous 2 years, current tobacco user, and positive drugs-of-abuse or alcohol screen at screening or Day -1 of Period 1. 5. History of meningococcal infection, or a first-degree relative with a history of meningococcal infection. 6. Body temperature ≥ 38.0°Celsius at screening or prior to (first) dosing in Period 1 or history of febrile illness, or other evidence of infection, within 14 days prior to (first) dosing. 7. History of procedures that could alter absorption or excretion of orally administered drugs. 8. A history of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs. 9. Major surgery within previous 4 weeks. 10. Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 5 half-lives (if known) or 30 days before (first) dosing, whichever is longer. 11. Donation of whole blood from 3 months prior to (first) dosing or of plasma from 30 days before (first) dosing, receipt of blood products within 6 months prior to (first) dosing, or receipt of a vaccine within 30 days prior to (first) dosing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tmax Of Danicopan Under Fed Conditions In Healthy Elderly Males | Up to 72 hours postdose |
| Area Under The Concentration Versus Time Curve From Time 0 To The Last Measurable Concentration (AUC0-t) Of Danicopan Under Both Fed And Fasted Conditions In Healthy Young Adults | Up to 72 hours postdose |
| Area Under The Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Danicopan Under Both Fed And Fasted Conditions In Healthy Young Adults | Up to 72 hours postdose |
| Maximum Observed Concentration (Cmax) Of Danicopan Under Both Fed And Fasted Conditions in Healthy Young Adults | Up to 72 hours postdose |
| Time To Maximum Observed Concentration (Tmax) Of Danicopan Under Both Fed And Fasted Conditions in Healthy Young Adults | Up to 72 hours postdose |
| AUC0-t Of Danicopan Under Fed Conditions In Healthy Elderly Males | Up to 72 hours postdose |
| AUC0-inf Of Danicopan Under Fed Conditions In Healthy Elderly Males | Up to 72 hours postdose |
| Cmax Of Danicopan Under Fed Conditions In Healthy Elderly Males | Up to 72 hours postdose |
Secondary
| Measure | Time frame |
|---|---|
| Number Of Healthy Young Adults And Healthy Elderly Males With Treatment-emergent Adverse Events | Day 1 (postdose) through follow-up (10 [+/- 2] days after last study drug administration) |
Countries
United States
Outcome results
None listed